CZ37625U1 - Dietary supplement - Google Patents
Dietary supplement Download PDFInfo
- Publication number
- CZ37625U1 CZ37625U1 CZ2023-41459U CZ202341459U CZ37625U1 CZ 37625 U1 CZ37625 U1 CZ 37625U1 CZ 202341459 U CZ202341459 U CZ 202341459U CZ 37625 U1 CZ37625 U1 CZ 37625U1
- Authority
- CZ
- Czechia
- Prior art keywords
- dietary supplement
- supplement according
- micronized
- pluvialis
- capsaicin
- Prior art date
Links
- 235000015872 dietary supplement Nutrition 0.000 title claims description 14
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 claims description 24
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 17
- 241000168517 Haematococcus lacustris Species 0.000 claims description 15
- 229960002504 capsaicin Drugs 0.000 claims description 12
- 235000017663 capsaicin Nutrition 0.000 claims description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- 239000001103 potassium chloride Substances 0.000 claims description 9
- 235000011164 potassium chloride Nutrition 0.000 claims description 9
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims description 8
- 235000017491 Bambusa tulda Nutrition 0.000 claims description 8
- 241001330002 Bambuseae Species 0.000 claims description 8
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims description 8
- 239000011425 bamboo Substances 0.000 claims description 8
- 235000013399 edible fruits Nutrition 0.000 claims description 8
- 239000000835 fiber Substances 0.000 claims description 8
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 claims description 8
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 claims description 7
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 claims description 7
- 229960001327 pyridoxal phosphate Drugs 0.000 claims description 7
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical group CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 5
- 229960003943 hypromellose Drugs 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 239000001069 triethyl citrate Substances 0.000 claims description 5
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 5
- 235000013769 triethyl citrate Nutrition 0.000 claims description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 229920002670 Fructan Polymers 0.000 claims description 3
- 239000004014 plasticizer Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- ZFTFOHBYVDOAMH-XNOIKFDKSA-N (2r,3s,4s,5r)-5-[[(2r,3s,4s,5r)-5-[[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-2-(hydroxymethyl)oxolan-2-yl]oxymethyl]-2-(hydroxymethyl)oxolane-2,3,4-triol Chemical class O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(OC[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 ZFTFOHBYVDOAMH-XNOIKFDKSA-N 0.000 claims description 2
- 239000001692 EU approved anti-caking agent Substances 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 235000012239 silicon dioxide Nutrition 0.000 claims description 2
- 241000195493 Cryptophyta Species 0.000 claims 1
- 238000002360 preparation method Methods 0.000 description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 6
- 229920001202 Inulin Polymers 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 229940029339 inulin Drugs 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000830535 Ligustrum lucidum Species 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- 210000000593 adipose tissue white Anatomy 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 238000007681 bariatric surgery Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 238000004260 weight control Methods 0.000 description 2
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000002567 Capsicum annuum Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- UFHFLCQGNIYNRP-VVKOMZTBSA-N Dideuterium Chemical compound [2H][2H] UFHFLCQGNIYNRP-VVKOMZTBSA-N 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 210000003486 adipose tissue brown Anatomy 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 239000001511 capsicum annuum Substances 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000021149 fatty food Nutrition 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000008798 inflammatory stress Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 229920000157 polyfructose Polymers 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/25—Synthetic polymers, e.g. vinylic or acrylic polymers
- A23L33/26—Polyol polyesters, e.g. sucrose polyesters; Synthetic sugar polymers, e.g. polydextrose
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Description
Doplněk stravyDietary supplement
Oblast technikyField of technology
Technické řešení představuje přípravek ze skupiny doplňky stravy pro posílení kontrolu tělesné hmotnosti.The technical solution is a preparation from the group of dietary supplements for strengthening body weight control.
Dosavadní stav technikyCurrent state of the art
Vzhledem k tomu, že téměř 40 % dospělých na světě má nadváhu nebo obezitu, obezita dosáhla pandemických rozměrů. Celosvětová prevalence obezity mezi lety 1975 a 2016 téměř ztrojnásobila. Udržování normální tělesné hmotnosti je zásadní pro prevenci běžných onemocnění, jako je hypertenze, hyperinzulinémie, inzulínová rezistence a diabetes typu 2, což jsou patologie, které zahrnují metabolický syndrom. Hubnutí je prvním krokem, který lékaři doporučují lidem s nadváhou se zvýšeným krevním tlakem. Mnoho pacientů však nedokáže zhubnout pouze změnou stravy a zvýšením fyzické aktivity. Chirurgické prostředky ke snížení hmotnosti (například bariatrická chirurgie, bandáž žaludku nebo svorkování) mohou mít závažné vedlejší účinky. Je zřejmé, že existuje naléhavá potřeba léků, které mohou lidem pomoci zhubnout, a doplňků stravy, které mohou zabránit přibírání na váze a udržet si zdravou tělesnou hmotnost.With nearly 40% of adults worldwide overweight or obese, obesity has reached pandemic proportions. The global prevalence of obesity nearly tripled between 1975 and 2016. Maintaining a normal body weight is essential for the prevention of common diseases such as hypertension, hyperinsulinemia, insulin resistance, and type 2 diabetes, pathologies that include the metabolic syndrome. Losing weight is the first step doctors recommend for overweight people with high blood pressure. However, many patients are unable to lose weight simply by changing their diet and increasing physical activity. Weight loss surgery (such as bariatric surgery, gastric banding, or stapling) can have serious side effects. Clearly, there is an urgent need for drugs that can help people lose weight and dietary supplements that can prevent weight gain and maintain a healthy body weight.
Existuje několik studií, které prokazují, že pravidelná konzumace vyšší dávek kapsaicinu skutečně urychluje metabolismus - spalování - a pomáhá hubnout.There are several studies that show that regular consumption of higher doses of capsaicin actually speeds up the metabolism - burning - and helps with weight loss.
Kapsaicin podle vědců z University of Wyoming aktivuje v celém těle receptory, které zahajují proces spalování energie. Tyto receptory se nacházejí v bílém a hnědém tuku. Právě bílý tuk, který se ukládá na břiše, bocích a zadku, je považován za tuk nedobrý a pro zdraví zhoubný. Dle studií kapsaicin dokáže stimulovat receptor zvaný potenciální vaniloidní 1 (TRPV1) receptor. Jeho aktivací je potlačována obezita související s vyšším příjmem tučné stravy.According to scientists from the University of Wyoming, capsaicin activates receptors throughout the body that start the process of burning energy. These receptors are found in white and brown fat. It is the white fat that is deposited on the abdomen, hips and buttocks that is considered bad fat and harmful to health. According to studies, capsaicin can stimulate a receptor called the receptor potential vanilloid 1 (TRPV1). Its activation suppresses obesity related to a higher intake of fatty food.
Kapsaicin má také protirakovinné účinky a snižuje riziko onemocnění diabetem a chorobami srdce.Capsaicin also has anti-cancer effects and reduces the risk of diabetes and heart disease.
Problémem při užívání kapsaicinu je podráždění sliznice trávicího traktu při vyšších dávkách. Tento nedostatek odstraňuje předložené technické řešení.A problem with the use of capsaicin is the irritation of the mucous membrane of the digestive tract at higher doses. This shortcoming is removed by the presented technical solution.
Terapie za pomoci molekulárního vodíku nabývá v současné době na významu. Řadou studií bylo prokázáno, že molekulární vodík alkalizuje a hydratuje buňky a redukuje zánětlivé procesy. Zároveň eliminuje kyselinu mléčnou, urychluje regeneraci, zvyšuje výkonnost a odstraňuje únavu. Je to velice silný antioxidant a má přímý vliv na ukončení chronických a akutních zánětů. Vodíková voda jako terapie je vhodná pro široké spektrum kožních onemocnění, jako je lupénka, ekzémy, zánětlivé onemocnění kůže. Její popíjení zvyšuje energii a pomáhá v boji proti civilizačním onemocněním, způsobených mimo jiné také každodenním stresem. Molekulární vodík snižuje zánětlivé procesy ve svalech a kloubech, tkáních, v orgánech a v cirkulaci krve a nastartuje očistné procesy metabolismu či odplavování odpadních látek a současně umožňuje samoléčící schopnost organismu.Therapy with the help of molecular hydrogen is currently gaining importance. A number of studies have shown that molecular hydrogen alkalizes and hydrates cells and reduces inflammatory processes. At the same time, it eliminates lactic acid, accelerates regeneration, increases performance and removes fatigue. It is a very strong antioxidant and has a direct effect on ending chronic and acute inflammation. Hydrogen water as a therapy is suitable for a wide range of skin diseases, such as psoriasis, eczema, inflammatory skin diseases. Drinking it increases energy and helps in the fight against civilizational diseases, caused, among other things, by everyday stress. Molecular hydrogen reduces inflammatory processes in muscles and joints, tissues, organs and blood circulation and starts the cleansing processes of metabolism or flushing away waste substances, and at the same time enables the self-healing ability of the organism.
Na rozdíl od konvenčních antioxidantů a protizánětlivých látek fyzikálně-chemické vlastnosti a biomedicínské studie působení molekulárního vodíku naznačují, že H2 má velký potenciál při zmírňování účinků nadměrného množství ROS (reaktivní formy kyslíku) a zánětu, viz. článek „Molecular hydrogen reduces acute exercise-induced inflammatory and oxidative stress status“, Free Radical Biology and Medicine, Vol. 129, December 2018, Pages 186-193, (https://linkinghub.elsevier.com/retrieve/pii/S0891584918311432). Pokusy bylo zjištěno, že antioxidační účinky molekulárního vodíku H2 se synergicky zvyšují v přítomnosti trehalózy.Unlike conventional antioxidants and anti-inflammatories, the physicochemical properties and biomedical studies of the action of molecular hydrogen indicate that H2 has great potential in mitigating the effects of excess ROS (reactive oxygen species) and inflammation, viz. article "Molecular hydrogen reduces acute exercise-induced inflammation and oxidative stress status", Free Radical Biology and Medicine, Vol. 129, December 2018, Pages 186-193, (https://linkinghub.elsevier.com/retrieve/pii/S0891584918311432). Experiments have shown that the antioxidant effects of molecular hydrogen H2 synergistically increase in the presence of trehalose.
- 1 CZ 37625 UI- 1 CZ 37625 UI
Trehalóza je v humánní medicíně hojně využívána například pro zabránění úbytku vody v buňkách (dehydrataci), proti vystavení buněk nadměrnému teplu, chladu nebo oxyradikálům, proti hypoxii až anoxii a proti hypoxicko - reoxygenačnímu poškození. Při styku trehalózy se střevní mikroflórou dochází k uvolnění molekulárního vodíku.Trehalose is widely used in human medicine, for example, to prevent loss of water in cells (dehydration), against exposure of cells to excessive heat, cold or oxyradicals, against hypoxia to anoxia, and against hypoxic-reoxygenation damage. When trehalose comes into contact with intestinal microflora, molecular hydrogen is released.
Prebiotika v tlustém střevě podporují růst laktobacilů a bifidobakterií, které produkují molekulární vodík, ten poté proniká do buněčných struktur, které mohou být poškozeny oxidativním stresem.Prebiotics in the colon support the growth of lactobacilli and bifidobacteria, which produce molecular hydrogen, which then penetrates cellular structures that may be damaged by oxidative stress.
Podstata technického řešeníThe essence of the technical solution
Přípravek podle technického řešení představuje doplněk stravy ve formě tablety nebo prášku. Tablety se polykají celé, zapíjejí se dostatečným množstvím tekutiny, ideálně vody. Prášek se rozpouští ve vodě a následný nápoj se vypije.According to the technical solution, the preparation is a dietary supplement in the form of a tablet or powder. The tablets are swallowed whole, with a sufficient amount of liquid, ideally water. The powder is dissolved in water and the subsequent drink is drunk.
Přípravek podle technického řešení obsahuje následující látky:According to the technical solution, the preparation contains the following substances:
Extrakt z plodů ptačího zobu lesklého (Ligustrum lucidum, 98% kyselina oleanolová)Ligustrum lucidum (Ligustrum lucidum, 98% oleanolic acid) fruit extract
Extrakt chilli (Capsicum annuum) enkapsulovaný v Haematococcus pluvialisChilli (Capsicum annuum) extract encapsulated in Haematococcus pluvialis
Desintegrovaná nebo mikronizovaná řasa H. pluvialisDisintegrated or micronized alga H. pluvialis
Mikronizovaná bambusová vlákninaMicronized bamboo fiber
Vitamín B6 (Pyridoxal-5-fosfát)Vitamin B6 (Pyridoxal-5-Phosphate)
Draslík nebo chlorid draselnýPotassium or potassium chloride
Dále může přípravek obsahovat další látky:In addition, the product may contain other substances:
Fruktany - inulin, oligofruktózy, hydrolyzovaný inulin, polyfruktózy, fruktooligosacharidy Protispékavé látky, nejčastěji oxid křemičitý a/nebo stearát hořečnatý Plastifikátory, nej častěji triethylcitrátFructans - inulin, oligofructoses, hydrolyzed inulin, polyfructoses, fructooligosaccharides Anti-caking agents, most often silicon dioxide and/or magnesium stearate Plasticizers, most often triethyl citrate
Kluzné látky, nejčastěji hypromelózaGlidants, most often hypromellose
AromataAroma
Příklady uskutečnění technického řešeníExamples of implementing a technical solution
Příklad 1Example 1
Složení přípravkuThe composition of the preparation
-2CZ 37625 UI-2CZ 37625 UI
Příklad 2Example 2
Složení přípravkuThe composition of the preparation
Příklad 3Example 3
Složení přípravkuThe composition of the preparation
Příklad 4Example 4
Složení přípravkuThe composition of the preparation
-3 CZ 37625 UI-3 CZ 37625 UI
Příklad 5Example 5
Složení přípravkuThe composition of the preparation
Příklad 6Example 6
Složení přípravkuThe composition of the preparation
Průmyslová využitelnostIndustrial applicability
Přípravek podle technického řešení lze opakovaně vyrobit a použít jako doplněk stravy pro 15 kontrolu tělesné hmotnosti.The preparation according to the technical solution can be repeatedly produced and used as a dietary supplement for 15 body weight control.
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CZ2023-41459U CZ37625U1 (en) | 2023-11-13 | 2023-11-13 | Dietary supplement |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CZ2023-41459U CZ37625U1 (en) | 2023-11-13 | 2023-11-13 | Dietary supplement |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CZ37625U1 true CZ37625U1 (en) | 2024-01-17 |
Family
ID=89661826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CZ2023-41459U CZ37625U1 (en) | 2023-11-13 | 2023-11-13 | Dietary supplement |
Country Status (1)
| Country | Link |
|---|---|
| CZ (1) | CZ37625U1 (en) |
-
2023
- 2023-11-13 CZ CZ2023-41459U patent/CZ37625U1/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2402342C2 (en) | Composition for body fat reduction | |
| US7976880B2 (en) | Pregnane glycoside compositions and Caralluma extract products and uses thereof | |
| JP5596704B2 (en) | Composition containing fucoxanthin extract | |
| RU2015103719A (en) | FIBER FIBER FOR USE IN TREATMENT OF AN ADDITIVE EFFECT OF NUTRITION OR MEDICINE IN RESPECT OF THE GASTROINTESTINAL TRACT | |
| MX2012009945A (en) | Lactic acid bacterium-containing preparation. | |
| CN102526445B (en) | Health-care medicament formula with functions of strengthening immunity, relieving physical fatigue and resisting tumor | |
| TWI830696B (en) | Compositions for inhibiting muscle fiber degeneration | |
| US20060045924A1 (en) | Dried fruit composition with laxative effects and method for administration thereof | |
| TW201206460A (en) | Anti-viral properties of Aloe vera and Acquired Immune Deficiency Syndrome (AIDS) treatment | |
| CN115210360A (en) | Novel lactobacillus reuteri LM1071 strain derived from breast milk, and composition for alleviating premenstrual syndrome comprising the same or culture thereof | |
| US11793845B2 (en) | Composition for ameliorating peripheral sensory neuropathy | |
| CN101721403A (en) | Application of fucoxanthin in aspect of losing weight | |
| CZ37625U1 (en) | Dietary supplement | |
| CN109965290B (en) | Meal replacement powder for improving intestinal flora and application thereof | |
| WO2016124080A1 (en) | Use of 20(r)-ginsenoside rg3 in preparation of drug for preventing or/and treating obesity and drug | |
| JP2023154540A (en) | Composition for preventing or improving age-related hearing loss | |
| CN108371709A (en) | Lycium ruthenicum tumor recovering gene enzyme | |
| JP2024520785A (en) | Compositions for improving gut microbial populations containing galactose | |
| CN103948591B (en) | A kind of slimming agents | |
| JP2009062348A (en) | Hypoglycemic action and blood sugar level elevation-suppressive action by seed ingredient of kenafs (kenaf and roselle) | |
| JP6476043B2 (en) | Preventive or therapeutic agent for peptic ulcer, and food additive for prevention or treatment | |
| JP7063514B2 (en) | An agent for preventing or improving orthostatic hypotension and a composition containing the same. | |
| CN111655250A (en) | Composition for preventing or improving nociceptive pain | |
| KR20140104090A (en) | A pharmaceutical composition for treating and preventing fatty liver diseases containing curcumin as an active ingredient | |
| CN109260235A (en) | A kind of application of composition in preparation prevention and treatment constipation drug or health care product |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG1K | Utility model registered |
Effective date: 20240117 |